Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singapore’s Dx Assay Pushing Fee-for-service Model In Companion Diagnostics

This article was originally published in PharmAsia News

Executive Summary

Dx assays Pte. Ltd. says its fee-for-service business model makes it a unique provider of companion diagnostics in a market set to boom globally as U.S. FDA and other regulators push for drug firms to develop diagnostics alongside drugs.

You may also be interested in...



FDA Releases Companion Dx Guidance Broad In Scope, Limited In Detail

FDA released long-awaited draft guidance on the development of drugs with companion diagnostics July 12, but the 12-page document’s concise nature left some in the industry longing for more insight.

As Asia Gets Richer, Singapore's EDB Turns Investments To Tech-enabled, Remote Monitoring Start-Ups

SINGAPORE - The Singaporean government's leading investments arm, EDB Investments, is increasingly betting on small-sized companies that leverage advanced communication technologies like mobile phones or remote monitoring to develop healthcare solutions

Dx Assays Opens R&D Lab As Singapore’s First Developer Of Molecular Diagnostic Assays

PERTH, Australia - Dx Assays, Singapore's first commercial developer of molecular diagnostic assays, opened its new R&D center in Singapore Sept. 8

Topics

Related Companies

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel